Information Provided By:
Fly News Breaks for May 22, 2017
PBYI
May 22, 2017 | 12:40 EDT
Credit Suisse analyst Alethia Young said she was surprised to find that the neratinib briefing documents posted ahead of Wednesday's FDA advisory committee meeting to discuss Puma Biotechnology's breast cancer treatment were "pretty clean" and contained "no big surprises." It seemed the documents were supportive of the efficacy and didn't provide much surprise on tolerability, though she is only "cautiously optimistic" while watching out for "any curveballs" when the panel meets, she tells investors. Young keeps an Outperform rating and $58 price target on Puma shares.
News For PBYI From the Last 2 Days
There are no results for your query PBYI